German health minister urges EU to clear 2nd booster for elderly

German Health Minister Karl Lauterbach speaks as he attends a news conference on the coronavirus disease (COVID-19) situation, in Berlin, Germany, March 25, 2022. REUTERS/Annegret Hilse/File Photo

Register now for FREE unlimited access to Reuters.com

Register

BERLIN, March 29 (Reuters) – Germany’s health minister said on Tuesday he would urge the European Union to back a fourth COVID-19 shot for people over the age of 60 years to boost immunity in the absence of vaccines that specifically protect against the Omicron variant.

Pointing to data from Israel, minister Karl Lauterbach said a recommendation was “urgently necessary” to reduce the risk of death from an infection and that he would raise the issue at a meeting of health ministers in Brussels on Tuesday.

EU regulator the European Medicines Agency (EMA) said on March 17 that there was not yet enough data to support a recommendation on the need for a second booster shot in the general population, while acknowledging that some member states had started such a campaign targeting the elderly.

Register now for FREE unlimited access to Reuters.com

Register

EMA added at the time that it was hoping for more data to guide a review later in the spring.

A study from Israel showed on Sunday that senior citizens who received a second booster of the Pfizer–BioNTech COVID-19 vaccination had a 78% lower mortality rate from the disease than those who had only one. read more

Earlier public health studies from Israeli had guided a decision by Germany in February to give a fourth shot to people aged 70 and older and to those at risk of severe disease. read more

Lauterbach said the booster strategy was urgent because he did not expect a vaccine adapted for new variants to become available before the autumn.

September is the month set for the launch of a shot that targets the dominant Omicron lineage, he said on Tuesday, but action was needed before then.

EMA’s leading vaccine expert said on March 17 he expected to receive trial data on COVID-19 vaccines tailored for the Omicron variant between April and the start of July. read more

Register now for FREE unlimited access to Reuters.com

Register

Additional reporting Miranda Murray
Editing by Madeline Chambers and Bernadette Baum

Our Standards: The Thomson Reuters Trust Principles.